Volver a Agenda
Session Chair(s)
Shaghig Palanjian, MBA
Vice President, Global Head, R&D QA and Compliance
Shire, United States
Learning Objective : Develop strategies for the design, implementation, and auditing consideration of GCP Compliance; Discuss company QMS needs in the changing product development paradigm.
Speaker(s)
Changing Drug Development Paradigms and Considerations for Quality Systems
Kirsten Ledwith Morasco
Compliance Implementation Services (CIS), United States
Vice President, Clinical and Quality Compliance
Panelist
James R. Dixon
PPD, United States
Senior Vice President, Quality and Enterprise Learning
Panelist
Mike Sobczyk, MSC
Gilead Sciences, Inc., United States
Exec. Director, R&D Quality and Compliance
Panelist
Marcia K. Horn, JD
ICAN, International Cancer Advocacy Network, United States
President and CEO
¿Tiene una cuenta?